Company Overview
Aeries Technology, Inc. operates as a provider of professional and technology consulting services across North America, the Asia Pacific region, and internationally, offering advisory support that includes senior leadership participation and strategic recommendations for operational modes. The company is situated within the Industrials sector, specifically focusing on the Consulting Services industry, which positions it as a service-oriented entity rather than a manufacturer or retailer of physical goods. In terms of scale, Aeries Technology, Inc. holds a market capitalization of $15.59M and generates annual revenue of $69.20M, employing a workforce of 1400 individuals. These figures indicate that the company operates with a relatively modest market valuation relative to its revenue stream, suggesting a small-cap status where earnings volatility often outweighs revenue stability in investor analysis. The disparity between the $69.20M in revenue and the $15.59M market cap highlights a significant difference between the company's operational scale and its current equity market assessment.
Financial Health
The company reported revenue of $69.20M for the trailing twelve months, while simultaneously recording a net income of $-2,922,000 and an EBITDA of $3.08M. The substantial gap between the positive EBITDA of $3.08M and the negative net income reveals a cost structure characterized by significant non-operating expenses or other comprehensive losses that erode bottom-line profitability despite healthy operational cash generation. The business generated free cash flow of $558,000, which indicates that the company retains cash from operations after capital expenditures, providing a degree of financial flexibility for liquidity management or debt servicing. Regarding profitability efficiency, the gross margin stands at 24.9%, reflecting the portion of revenue remaining after direct costs, while the operating margin is 4.4% and the profit margin is -4.2%. The negative profit margin of -4.2% confirms that the company is currently unprofitable on a net basis, whereas the positive operating margin suggests that core business operations before interest and taxes are generating value. On the balance sheet, the company holds cash of $2.57M against total debt of $14.36M, creating a net debt position, and the debt-to-equity ratio is listed as N/A due to the absence of shareholder equity in the standard calculation context. The current ratio is 0.75, which indicates that the company's current assets are insufficient to cover its current liabilities without external financing or asset liquidation. Return on Equity is N/A because the company has no positive equity to return value to, while Return on Assets stands at 2.9%, showing that the asset base generates a small positive return relative to its total size.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A because the company is currently unprofitable, and the forward P/E is also N/A, implying that analysts cannot yet project a normalized earnings multiple without a return to profitability. The price-to-book ratio is -12.93, which indicates that the stock trades at a negative multiple of its book value, a metric often seen in distressed or turnaround situations where market value diverges significantly from accounting book value. Alternative valuation metrics such as the price-to-sales ratio of 0.23 and the EV/EBITDA of 8.87 provide context for valuation on revenue and cash flow bases, suggesting the company trades at a fraction of its sales revenue and at a compressed multiple of its enterprise earnings before interest, taxes, and depreciation. The 52-week high is $1.52 and the 52-week low is $0.26, meaning the current price sits significantly below the 52-week high but above the floor, reflecting a wide trading range typical of small-cap biotech or distressed industrials. The beta value is -0.28, which means the stock exhibits an inverse correlation to the broader market and moves in the opposite direction of the S&P 500 with reduced volatility compared to the market index.
Growth & Income
Revenue growth year-over-year is -0.8%, while earnings growth year-over-year is -67.8%, indicating that earnings are declining at a much faster rate than revenue, which suggests deteriorating operational efficiency or increasing cost pressures that are not immediately reflected in top-line sales. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available capital and retains earnings rather than distributing them to shareholders. Since the company is not a dividend payer, the growth and income profile is entirely dependent on potential future capital appreciation driven by operational turnarounds or strategic acquisitions. The overall growth and income profile is characterized by negative earnings momentum and a lack of current yield, requiring investors to rely on valuation compression and potential operational improvements for future returns.